ECM remodeling in hypertensive heart disease.

By B. Berk, K. Fujiwara, S. Lehoux. Journal of Clinical Investigation, 2007

885 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

PAI-1 in Tissue Fibrosis (2012, neutral): “…cardiac hypertension, myocardial infarction (MI), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH) (Brunt, 2004; Jansen, 2004; Berk et al., 2007; Varga and Abraham, 2007; Vaughan et al., 2007; Wynn, 2008; Pohlers et al., 2009; Ellmers, 2010; Ghosh, 2010; Leask, 2010;…”
Fibroblasts in fibrosis: novel roles and mediators (2014, background): “The net effect of multiple stimuli that recapitulate the milieu in human tissues is difficult to reproduce in the laboratory, although initial efforts using ex vivo organ cultures such as skin (Yasuoka et al., 2008; Yamaguchi et al., 2012) are promising.”
Irbesartan in patients with heart failure and preserved ejection fraction. (2008, background): “Mean — yr 72±7 72±7 ≥75 yr — no. (%) 716 (35) 697 ( 34 )”
The Pathogenesis of Cardiac Fibrosis (2013, neutral): “Pressure overload, induced by hypertension or aortic stenosis, results in extensive cardiac fibrosis that is initially associated with increased stiffness and diastolic dysfunction; a persistent pressure load may eventually lead to ventricular dilation and combined diastolic and systolic heart failu”
Cardiac fibrosis. (2020, background): “Myocardial fibrosis, the expansion of the cardiac interstitium due to net accumulation of ECM proteins, accompanies most cardiac pathologic conditions.(2,3) Although in most myocardial diseases, the extent of car-”